Researchers at QurAlis have discovered a molecule with the potential to act as a treatment for amyotrophic lateral sclerosis (ALS), in addition to a new therapeutic target for the disease. The findings from both projects were presented at the 31st International Symposium on ALS/MND,…
QurAlis Working on New ALS Therapy to Harness Benefits Without Side Effects
A method that measures tiny amounts of aggregated TDP-43 protein in the cerebrospinal fluid may have the potential to detect amyotrophic lateral sclerosis (ALS) in the early stages of the disease, potentially before symptom onset, a study reports. The study,…
Target ALS is launching an expansive $15 million research initiative aimed at discovering biomarkers and developing new scientific resources for amyotrophic lateral sclerosis (ALS). The Target ALS Diagnosis Initiative, touted as the first of its kind, will create grants and scientific resources to identify needed biomarkers. Such indicators allow…
It’s time again to send our annual Christmas letter and picture card to our friends and family. Since my daughter could talk, I’ve kept a list of cute things the kids say throughout each year. I pick the best to include in our letter. When Sara was 2, we…
Cytokinetics is preparing a global Phase 3 trial that will enroll more than 500 people with early amyotrophic lateral sclerosis (ALS) to test its investigational therapy reldesemtiv in slowing progressive muscle weakness, the company announced. Details from the trial design were shared at the 31st International Symposium…
Columns
We Are All the Stuff of Legends
“All the world’s a stage, And all the men and women merely players; They have their exits and their entrances; And one man in his time plays many parts …” – William Shakespeare Some months back, I…
The anticonvulsant ezogabine can significantly reduce abnormal motor neuron excitability in people with amyotrophic lateral sclerosis (ALS), a clinical trial has found. The findings support further investigation of ezogabine, and into the possible utility of neuron excitability as a measurement of disease in ALS, researchers…
One of the first symptoms of ALS I experienced was a sudden weakness in my legs and feet. This meant that without warning, whenever I walked I felt as if I had stepped in a hole, and more than once I ended up taking a nasty fall. Even when I…
Actimed Therapeutics has obtained the rights to develop and commercialize ACM-002 (S-oxprenolol) for the treatment of amyotrophic lateral sclerosis (ALS) in Europe, the company announced. The rights, licensed from patent owner Charité University Medicine Berlin, cover all major European markets, including France, Germany, the U.K., Italy,…
The U.S. Senate has passed a bill that may make it easier for people with amyotrophic lateral sclerosis (ALS) to access disability benefits. The proposed legislation, the ALS Disability Insurance Access Act of 2019, still must be approved by the U.S. House of Representatives. If enacted, the legislation…
Recent Posts
- We must each find our own way as we learn to live with ALS
- Exposure to pesticide HCB may raise risk of ALS, new study finds
- Swallowing problems affect 1 in 3 hospitalized ALS patients: Study
- Scientists identify blood markers that may predict ALS progression
- ALS caregivers across Canada can now access free professional counseling